James Cooke

Email: abpcbz@r.postjobfree.com

Address: ** ********** ***

City: Glen Mills

State: PA

Zip: 19342

Country: USA

Phone: 610-***-****

Skill Level: Management

Salary Range: $120,000

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

JAMES F. COOKE, JR., MBA

48 Strickland Way, Glen Mills, Pa. 19342 abpcbz@r.postjobfree.com

610-***-**** (h) 904-***-**** (c) http://www.linkedin.com/in/jamescooke1

STRATEGIC PRODUCT MARKETING

Experience successfully launching branded and generic products in domestic as well as global markets through unique product positioning and messaging. Integrates medical education, publication strategies, thought leaders and effective sales management techniques to optimize tactical implementation. Combines internal stakeholder collaboration with in-depth market analyses to develop pricing and pull through strategies. Proven ability to develop sales and marketing staff for greater responsibility. Knowledge of to how leverage legal, clinical, regulatory and contracting opportunities to maintain revenue and increase profitability during various stages of the product lifecycle.

Therapeutic areas of knowledge: anti-infective, cardiovascular, depression, dermatology and gastrointestinal

RECENT PROFESSIONAL EXPERIENCE

BENG CONSULTING, INC, York, Pa. 2012 - present

Healthcare Marketing Consultant

Provide commercial guidance to healthcare-related companies using my diverse operational background and extensive network to successfully address a variety of business challenges.

PFIZER/WYETH, INC., Collegeville, Pa. 1995 - 2011

World`s largest pharmaceutical company with annual revenues of $70B and 116,500 employees in 150 countries.

Product Director, Anti-infective Global Strategy 2006 -- 2011

Tazocin: Focused on maintaining global market share in face of generic competition by leveraging two key regulatory strategies that held generic competitors to the same standards as Wyeth for treating critically ill patients. Achieved net sales of $600M (110% of 2007 budget) launching new Tazocin formulation in 60 countries with no supply interruptions despite the regulatory and logistical complexities of replacing 55 million vials, each with different labeling and packaging requirements.

Tygacil: In addition to the Tazocin duties, successfully led Tygacil product positioning and launch in the Asia-Pacific region that included medical education and thought leader development. Created effective Asia/Pacific regional microbiology testing manual/training program to cut false-positive resistance testing to almost zero, making clinicians confident in prescribing Tygacil.

District Sales Manager 2001 -- 2006

Led team of 10 primary care sales representatives to expand sales in North Florida and South Georgia for Altace, Effexor XR, Protonix and Zosyn (Tazocin). Maintained consistent top 5 ranking in sales out of 40 districts through effective relationship building, product information dissemination with 20 key cardiologists and endocrinologists. Achieved Zosyn annual sales of $750,000 and consistently ranked in top 5 for the region.

Successfully mentored sales team by developing four to be promoted to specialty positions.

Senior Product Manager, Altace 2000 -- 2001

Led turnaround of sales for underperforming Altace by leveraging new risk reduction data. Developed successful co-promotion partnerships with King Pharmaceuticals for ahead-of-schedule product re-launch.

Drove newly positioned Altace to $300M in 2001 against $250M budget, versus an actual of $165M in 2000.

Product Manager, Cardiovasculars 1997 - 2000

P&L responsibility for ZIAC and ZEBETA, an anti-hypertensive franchise promoted in partnership with P&G.

Managed a co-promotion involving 800 sales representatives including personal and non- personal tactics that merchandised phase IV comparative clinical data to achieve peak annual sales of $265M.

JAMES F. COOKE, JR. PAGE TWO

Product Manager, ESI Lederle Generics (Wyeth) 1995 - 1996

P&L oversight for 275 SKU generic oral product portfolio that focused on identifying ANDA opportunities and NDA rollovers. Secured regulatory approval, planned timely launches and developed successful retail chain, wholesale and independent pharmacy marketing strategies which achieved a net sales goal of $200M.

KEY ACCOMPLISHMENTS FROM RECENT ASSIGNMENTS

Developed regional launch tools for Tygacil (injectable antibiotic) in 12 Asia/Pacific markets. Combined data from phase III clinical studies with Asia-Pac patient treatment protocols to create a comprehensive medical education platform of interactive presentation slide decks, websites and speaker programs to accelerate product adoption. These initiatives helped Tygacil reach 105% of 2008 goal and 111% of 2009 goal in the region.

Implemented a post generic pricing/contracting strategy for Tazocin (injectable antibiotic) in the EU market. An in-depth analysis of other injectable antibiotics with similar commercial size, pricing and physician preference revealed an opportunity for unmet market demand. A strategy including legal, regulatory and contracting components resulted in 2008 and 2009 net sales that were 128% and 111% of goal, respectively.

Grew Altace (cardiovascular) district market share to 14% versus a national average of 9.5%. As a district sales manager, trained 10 sales representatives on consultative disease-state selling techniques, enabling the team to attain the highest market share in the nation. This was achieved by giving the team a level of knowledge and confidence to make more relevant patient-focused presentations to accelerate market share growth.

Led product positioning and re-launch of Altace within five months of FDA approval. As the senior product manager, utilized quantitative and qualitative data to win the co-promotion agreement with King Pharmaceuticals. Led the market research to develop the strategy and tactics that supported 2,200 sales representatives to grow the market share from 4.3% to 7.6% (15 competitive products) over a 12 month period.

Developed a comprehensive end stage product lifecycle strategy for Ziac (cardiovascular). First, pediatric studies were conducted to gain a six month market exclusivity extension, maintaining $125 million in revenue that would have been lost to generic competition. Secondly, data analysis revealed that focusing on 16,000 active prescribers would maintain prescription growth. Lastly, took advantage of a clause in the supply agreement to reduce COGS by 80%, increasing direct brand profit by $60 million over a three year period.

Reached $200 million net sales target for generic oral product portfolio. Managing a 275 SKU product line, with declining selling prices due to heavy competition, customized promotional programs were developed targeting specific drug store chains and wholesalers. By focusing on the anticipated growth rates of specific molecules, in addition to leveraging older products, unit volume and price points on newer compounds were maintained in order to reach sales targets.

PRIOR PROFESSIONAL EXPERIENCE

Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) 1986 - 1995

* Manager, Marketing Research

* Manager, Managed Care Marketing

* Professional Sales Representative (Dermik Labs - division of RPR)

EDUCATION & TRAINING

Master`s Degree in Business Administration, Marketing, University of Phoenix, Jacksonville, Fla., 2006

Bachelor`s Degree in Political Science, Loyola College, Baltimore, Md.

Drug Development, Wyeth Research and Development, Collegeville, Pa.

Contact this candidate